ReviewCurrent pharmaceutical design2025
Small Intestinal Bacterial Overgrowth (SIBO) - Prevention and Therapeutic Role of Nutrition, Prebiotics, Probiotics, and Prokinetics.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inhibitory Effects of Oxytocin on Jejunal Migrating Myoelectric Complex Activity in Fasted Rats: Role of Oxytocin and GLP-1 Receptors.Life (Basel, Switzerland) · 2026Article
- Prevalence and Impact on Quality of Life of Small Intestinal Bacterial Overgrowth (SIBO)-Related Symptoms in Patients with Upper Gastrointestinal Cancer.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small Intestinal Bacterial Overgrowth (SIBO) is a condition marked by an increased proliferation of bacteria in the small intestine. This leads to a range of GI symptoms and nutritional issues. This article examines the preventive and therapeutic roles of nutrition, prebiotics, probiotics, and prokinetics in managing SIBO. Finding the prevalence of SIBO in the general population is challenging due to challenges in diagnosis and different diagnostic methods. Nevertheless, SIBO has been linked to several clinical conditions, such as obesity, celiac disease, irritable bowel syndrome, inflammatory bowel disease, and hepatic cirrhosis. The connection between SIBO and obesity remains controversial and unclear, with contraindicating evidence regarding its prevalence and association with body mass index (BMI). Anatomical changes from surgeries may also contribute to the development of SIBO, and disruptions in the migrating motor complex (MMC) can facilitate intestinal permeability. SIBO can lead to significant malabsorption of nutrients, including carbohydrates, fats, proteins, and iron, resulting in deficiencies and malnourishment. Additionally, increased levels of immunoglobulins observed point toward a possible immune response to bacterial overgrowth. Hence, understanding the prevalence, clinical manifestations, and nutritional impacts of SIBO is crucial for effective prevention and management. This article underscores the potential benefits of nutrition, including prebiotics and probiotics, in modulating gut microbiota and managing SIBO. Furthermore, prokinetics that enhance gastrointestinal motility may offer possible therapeutic advantages in the future. Continued research is necessary to clarify the underlying mechanisms and refine treatment strategies for SIBO.
Indexed as
Identifiers
40296627What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.